Respiratory illness during winter: A cohort study of urban children from temperate Australia

Respiratory illness during winter: A cohort study of urban children from temperate Australia
复制标题

DOI:
10.1111/j.1440-1754.2005.00561.x
复制
发表时间:
2005-03-01
影响因子:
1.7
通讯作者:
Nolan, TM
Nolan, TM
中科院分区:
医学4区
文献类型:
--
作者:
Lambert, SB;O'Grady, KF;Nolan, TM

文献摘要

被引文献

相似文献

目的:研究的流行病学和负担的呼吸道疾病在冬季的城市儿童从温带Australia.Methods:我们进行了队列研究的健康墨尔本儿童,年龄从12至71个月。父母保持每天的呼吸道症状日记和记录资源使用时,流感样疾病(ILI)occupational.Results:118名儿童有137 ILI发作超过12周的率为0.53 ILI发作每个儿童月(95%CI 0.44-0.61)。ILI的风险因素包括年龄较小,家庭中居住的人较少,结构性暴露于家庭外的其他儿童以及较高的家庭收入。Epplastic的平均持续时间为10.4天,其中64次就诊于全科医生(每100次发作中有46.7次GP就诊),27个抗生素疗程(每100次发作中有19.7个抗生素疗程),3次住院过夜(每100次发作中有2.2次住院)。父母报告说,平均11.7小时多余的时间花在照顾一个孩子每epission.Conclusions:呼吸系统疾病是一种常见的,在很大程度上被忽视的疾病在澳大利亚儿童的原因。需要病原体特异性数据,以更好地评估现有和正在开发的疫苗及其他治疗方案可能产生的影响。
Objective: To examine the epidemiology and burden of respiratory illness during winter in urban children from temperate Australia.Methods: We conducted a cohort study of healthy Melbourne children, aged from 12 to 71 months. Parents kept a daily respiratory symptom diary and recorded resource use when an influenza-like illness (ILI) occurred.Results: One-hundred and eighteen children had 137 ILI episodes over 12 weeks for a rate of 0.53 ILI episodes per child-month (95% CI 0.44-0.61). Risk factors for ILI included younger age, fewer people residing in the household, structured exposure to other children outside the home, and a higher household income. Episodes had a mean duration of 10.4 days with 64 visits to a general practitioner (46.7 GP visits per 100 episodes), 27 antibiotic courses prescribed (19.7 antibiotic courses per 100 episodes), and three overnight hospitalizations (2.2 admissions per 100 episodes). Parents reported an average of 11.7 h excess time spent caring for a child per episode.Conclusions: Respiratory illnesses are a common and largely neglected cause of illness in Australian children. Pathogen-specific data are required to better assess the likely impact of available and developing vaccines and other treatment options.